Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.68 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.65 |
| ▸ | KRAS | P01116 | 2/20 | 0.64 |
| ▸ | NT5E | P21589 | 1/20 | 0.63 |
| ▸ | RNASEL | Q05823 | 4/20 | 0.62 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.62 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.62 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.60 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.60 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.60 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.59 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.59 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.59 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.59 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.59 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.59 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.58 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.58 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.57 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15747230 | 1.00 | TGM2 (0.68) | TGM2FUT5KRASNT5ERNASEL | |
| SCHEMBL23149534 | 1.00 | TGM2 (0.68) | TGM2FUT5KRASNT5ERNASEL | |
| SCHEMBL20850065 | 1.00 | TGM2 (0.68) | TGM2FUT5KRASNT5ERNASEL | |
| SCHEMBL720115 | 1.00 | TGM2 (0.68) | TGM2FUT5KRASNT5ERNASEL | |
| SCHEMBL21715304 | 0.99 | TGM2 (0.69) | TGM2FUT5KRASNT5ERNASEL | |
| SCHEMBL26067682 | 0.99 | TGM2 (0.69) | TGM2FUT5KRASNT5ERNASEL | |
| SCHEMBL21715305 | 0.99 | TGM2 (0.69) | TGM2FUT5KRASNT5ERNASEL | |
| SCHEMBL21184323 | 0.95 | TGM2 (0.68) | TGM2FUT5KRASNT5ERNASEL | |
| SCHEMBL19325472 | 0.95 | TGM2 (0.68) | TGM2FUT5KRASNT5ERNASEL | |
| SCHEMBL18763616 | 0.95 | TGM2 (0.68) | TGM2FUT5KRASNT5ERNASEL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1961 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748451-A2 | ANTISENSE OLIGONUCLEOTIDES AND USES THEREOF | Fundació Centre de Regulació Genòmica (ES) | 2026-05-27 | — | — | EP | claimed |
| WO-2026103936-A1 | CHEMICALLY MODIFIED CIRCULAR RNA MOLECULE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海元码智药生物技术有限公司 | 2026-05-21 | — | — | WO | claimed |
| CN-122060818-A | Chemically modified circular RNA molecules, methods of making and uses thereof | 上海元码智药生物技术有限公司 | 2026-05-19 | — | — | CN | claimed |
| EP-4689113-A1 | COMPOSITIONS AND METHODS FOR THE TARGETING OF LPA | Scribe Therapeutics Inc. (US) | 2026-02-11 | — | — | EP | claimed |
| EP-4602159-A2 | ENGINEERED TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE VARIANTS | Codexis, Inc. (US) | 2025-08-20 | — | — | EP | claimed |
| US-20250177317-A1 | SELECTIVE AGONISM OF SPECIFIC PATTERN RECOGNITION RECEPTORS IN mRNA CONSTRUCTS FOR SAFE, EFFECTIVE AND DURABLE VACCINES | CELESTIAL THERAPEUTICS, INC. | 2025-06-05 | — | — | US | claimed |
| CN-120051565-A | Engineered terminal deoxynucleotidyl transferase variants | 科德克希思公司 | 2025-05-27 | — | — | CN | claimed |
| WO-2025102115-A1 | METHOD FOR DETECTING CAPPED RNA MOLECULES | THE UNIVERSITY OF QUEENSLAND (AU) | 2025-05-22 | — | — | WO | claimed |
| WO-2025096982-A1 | TRANS AMPLIFYING RNAS COMPRISING CHEMICALLY MODIFIED NUCLEOBASES | AMPLITUDE THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | claimed |
| WO-2025072742-A9 | TRIGGER NUCLEIC ACIDS AND RNA-BINDING PROTEINS FOR UPREGULATING GENE EXPRESSION | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2025-05-01 | — | — | WO | claimed |
| EP-3950699-A1 | RNA CAPPING METHOD, PRODUCTION METHOD FOR MODIFIED RNA, AND MODIFIED RNA | Kyoto University (JP) | 2022-02-09 | — | — | EP | claimed |
| US-11142788-B2 | Isolation of target nucleic acids | GENETICS RESEARCH, LLC (US) | 2021-10-12 | — | — | US | claimed |
| US-20210052706-A1 | COMPOSITIONS AND METHODS FOR FACILITATING DELIVERY OF SYNTHETIC NUCLEIC ACIDS TO CELLS | TRANSLATE BIO MA, INC. (US) | 2021-02-25 | — | — | US | claimed |
| WO-2020204130-A1 | RNA CAPPING METHOD, PRODUCTION METHOD FOR MODIFIED RNA, AND MODIFIED RNA | 国立大学法人京都大学 | 2020-10-08 | — | — | WO | claimed |
| US-20180355419-A1 | ISOLATION OF TARGET NUCLEIC ACIDS | HARBINGER HEALTH, INC. | 2018-12-13 | — | — | US | claimed |
| US-20180355406-A1 | POLYNUCLEIC ACID MOLECULE ENRICHMENT METHODOLOGIES | GENETICS RESEARCH, LLC, D/B/A ZS GENETICS, INC. | 2018-12-13 | — | — | US | claimed |
| US-20180311176-A1 | NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACID COMPLEXES | TRANSLATE BIO MA, INC. (US) | 2018-11-01 | — | — | US | claimed |
| US-20140170689-A1 | Modified Diguanylate Cyclase-Phosphodiesterase and Method for Enzymatic Production of Cyclic-diGMP | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2014-06-19 | — | — | US | claimed |
| US-20050037394-A1 | preparing transcription reaction mixture comprising mutated polymerase, modified nucleotide triphosphates (NTPs), magnesium ions and oligonucleotide templates, partitioning high affinity nucleic acids, then replicating; point mutations; increased stability and half life | ARCHEMIX CORPORATION | 2005-02-17 | — | — | US | claimed |
| US-20040197804-A1 | Method for in vitro selection of 2'-substituted nucleic acids | ARCHEMIX CORPORATION | 2004-10-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180311176-A1 | NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACID COMPLEXES | DIS3, SYNCRIP, EXOSC5 | TGM2 3729/4885FUT5 3789/4885KRAS 236/4885 |
| US-20210052706-A1 | COMPOSITIONS AND METHODS FOR FACILITATING DELIVERY OF SYNTHETIC NUCLEIC ACIDS TO CELLS | NSUN3, RNGTT, CSGALNACT1 | TGM2 890/4885FUT5 21/4885KRAS 1950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.